Show simple item record

dc.contributor.authorGkogkas, Christos G.en_US
dc.contributor.authorKhoutorsky, Arkadyen_US
dc.contributor.authorCao, Ruifengen_US
dc.contributor.authorJafarnejad, Seyed Mehdien_US
dc.contributor.authorPrager-Khoutorsky, Mashaen_US
dc.contributor.authorGiannakas, Nikolaosen_US
dc.contributor.authorKaminari, Archontiaen_US
dc.contributor.authorFragkouli, Apostoliaen_US
dc.contributor.authorNader, Karimen_US
dc.contributor.authorPrice, Theodore J.en_US
dc.contributor.authorKonicek, Bruce W.en_US
dc.contributor.authorGraff, Jeremy R.en_US
dc.contributor.authorTzinia, Athina K.en_US
dc.contributor.authorLacaille, Jean-Claudeen_US
dc.contributor.authorSonenberg, Nahumen_US
dc.date.accessioned2015-03-31T21:39:08Z
dc.date.available2015-03-31T21:39:08Z
dc.date.created2014-11-26
dc.identifier.issn2211-1247en_US
dc.identifier.urihttp://hdl.handle.net/10735.1/4416
dc.description.abstractFragile X syndrome (FXS) is the leading genetic cause of autism. Mutations in Fmr1 (fragile X mental retardation 1 gene) engender exaggerated translation resulting in dendritic spine dysmorphogenesis, synaptic plasticity alterations, and behavioral deficits in mice, which are reminiscent of FXS phenotypes. Using postmortem brains from FXS patients and Fmr1 knockout mice (Fmr1(-/y)), we show that phosphorylation of the mRNA 5' cap binding protein, eukaryotic initiation factor 4E (eIF4E), is elevated concomitant with increased expression of matrix metalloproteinase 9 (MMP-9) protein. Genetic or pharmacological reduction of eIF4E phosphorylation rescued core behavioral deficits, synaptic plasticity alterations, and dendritic spine morphology defects via reducing exaggerated translation of Mmp9 mRNA in Fmr1(-/y) mice, whereas MMP-9 overexpression produced several FXS-like phenotypes. These results uncover a mechanism of regulation of synaptic function by translational control of Mmp-9 in FXS, which opens the possibility of new treatment avenues for the diverse neurological and psychiatric aspects of FXS.; Copyrighten_US
dc.description.sponsorship"This work was supported by a CIHR operating grant to N.S. (MOP-114994) and J.-C.L. (MOP-125985), the Azrieli Foundation and Brain Canada team grant to N.S. and J.-C.L., the Fonds de la Recherche du Québe-Santé (grant to J.-C.L. FRQS; Groupe de Recherche sur le Système Nerveux Central). J.-C.L. is the recipient of the Canada Research Chair in Cellular and Molecular Neurophysiology. C.G.G. received support from the Wellcome Trust-University of Edinburgh Institutional Strategic Support Fund. Human tissue was obtained from the NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore and the Harvard Brain Tissue Resource Center (grant number R24-MH 068855)."en_US
dc.publisherCell Pressen_US
dc.relation.urihttp://dx.doi.org/10.1016/j.celrep.2014.10.064en_US
dc.rightsCC BY−NC−ND 3.0 (Attribution−NonCommercial−NoDerivatives)en_US
dc.rights©2014 The Authorsen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/en_US
dc.subjectFragile X syndromeen_US
dc.subjectEukaryotic Initiation Factor-4E (eIF4E)en_US
dc.subjectPhosphorylationen_US
dc.subjectMice--Diseases--Researchen_US
dc.subjectMatrix Metalloproteinase 9en_US
dc.subjectMessenger RNAen_US
dc.titlePharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-Like Phenotypesen_US
dc.typeTexten_US
dc.type.genrearticleen_US
dc.identifier.bibliographicCitationGkogkas, Christos G., Arkady Khoutorsky, Ruifeng Cao, Seyed Mehdi Jafarnejad, et al. 2014. "Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses Fragile X syndrome-like phenotypes." Cell Reports 9(5): doi:10.1016/j.celrep.2014.10.064.en_US
dc.source.journalCell Reportsen_US
dc.identifier.volume9en_US
dc.identifier.issue5en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY−NC−ND  3.0 (Attribution−NonCommercial−NoDerivatives)
Except where otherwise noted, this item's license is described as CC BY−NC−ND 3.0 (Attribution−NonCommercial−NoDerivatives)